Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 1
1996 1
1998 7
1999 3
2000 4
2001 7
2002 16
2003 8
2004 27
2005 18
2006 18
2007 28
2008 17
2009 13
2010 16
2011 17
2012 16
2013 10
2014 20
2015 16
2016 12
2017 10
2018 11
2019 10
2020 6
2021 12
2022 9
2023 4
2024 10
2025 12
2026 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

327 results

Results by year

Filters applied: . Clear all
Page 1
Treatment of Anal High-Grade Squamous Intraepithelial Lesions to Prevent Anal Cancer.
Palefsky JM, Lee JY, Jay N, Goldstone SE, Darragh TM, Dunlevy HA, Rosa-Cunha I, Arons A, Pugliese JC, Vena D, Sparano JA, Wilkin TJ, Bucher G, Stier EA, Tirado Gomez M, Flowers L, Barroso LF, Mitsuyasu RT, Lensing SY, Logan J, Aboulafia DM, Schouten JT, de la Ossa J, Levine R, Korman JD, Hagensee M, Atkinson TM, Einstein MH, Cracchiolo BM, Wiley D, Ellsworth GB, Brickman C, Berry-Lawhorn JM; ANCHOR Investigators Group. Palefsky JM, et al. N Engl J Med. 2022 Jun 16;386(24):2273-2282. doi: 10.1056/NEJMoa2201048. N Engl J Med. 2022. PMID: 35704479 Free PMC article. Clinical Trial.
Treatment included office-based ablative procedures, ablation or excision under anesthesia, or the administration of topical fluorouracil or imiquimod. The primary outcome was progression to anal cancer in a time-to-event analysis. ...
Treatment included office-based ablative procedures, ablation or excision under anesthesia, or the administration of topical fluorouracil or …
Radiotherapy versus imiquimod for complex lentigo maligna: A phase 3 randomized clinical trial.
Hong AM, Lo SN, Fogarty GB, Stretch J, Wang W, Fernandez-Penas P, Martin RCW, Foote M, Soyer HP, Ruben J, Mar V, Rocha L, Festa-Neto C, Wratten C, Hogarth S, Collgros H, Glanz A, Gouveia BM, Scolyer RA, King MT, Guitera P. Hong AM, et al. J Am Acad Dermatol. 2025 Nov;93(5):1251-1260. doi: 10.1016/j.jaad.2025.07.028. Epub 2025 Jul 17. J Am Acad Dermatol. 2025. PMID: 40683357 Clinical Trial.
Patients were randomized to radiotherapy or imiquimod. The primary end point was treatment failure at 24 months. Secondary end points included response at 6 months, development of invasive disease, toxicity and HRQL. ...The trial is underpowered due to early cessation of r …
Patients were randomized to radiotherapy or imiquimod. The primary end point was treatment failure at 24 months. Secondary end points …
Pilot clinical trial of neoadjuvant toll-like receptor 7 agonist (Imiquimod) immunotherapy in early-stage oral squamous cell carcinoma.
Yoon AJ, Carvajal RD, Graboyes EM, Kaczmar JM, Albergotti WG, Kejner AE, Troob SH, Philipone E, Anoma JS, Armeson KE, Hill EG, Richardson MS, Woods TR, Chera BS, Nourollah-Zadeh F, Lee BJ, Pandruvada S, Kourtidis A, Kingsley C, O'Quinn EC, Mills S, Jordan VC, Spencer M, Fails D, McKee TD, Zaidi M, Brisendine A, Horn S, Mehrotra S, Ogretmen B, Newman JG. Yoon AJ, et al. Front Immunol. 2025 Jan 27;16:1530262. doi: 10.3389/fimmu.2025.1530262. eCollection 2025. Front Immunol. 2025. PMID: 39931064 Free PMC article. Clinical Trial.
We report a single-arm, open-label, pilot clinical trial assessing the efficacy and safety of topical toll-like receptor-7 (TLR-7) agonist, imiquimod, utilized in a neoadjuvant setting in early-stage oral squamous cell carcinoma (OSCC). ...The median follow-up time was 17 …
We report a single-arm, open-label, pilot clinical trial assessing the efficacy and safety of topical toll-like receptor-7 (TLR-7) agonist, …
Topical TLR7 agonist and radiotherapy in patients with metastatic breast cancer.
Adams S, Demaria S, Rinchai D, Wang E, Novik Y, Oratz R, Fenton-Kerimian M, Levine PG, Li X, Marincola F, Jin P, Stroncek D, Goldberg J, Bedognetti D, Formenti SC. Adams S, et al. J Immunother Cancer. 2025 Apr 5;13(4):e011173. doi: 10.1136/jitc-2024-011173. J Immunother Cancer. 2025. PMID: 40187749 Free PMC article. Clinical Trial.
We conducted a phase I/II trial combining topical imiquimod (IMQ, a TLR-7 agonist) and local radiotherapy (RT) in patients with metastatic breast cancer accompanied by longitudinal transcriptional analysis of tumor biopsies. ...
We conducted a phase I/II trial combining topical imiquimod (IMQ, a TLR-7 agonist) and local radiotherapy (RT) in patients with metas …
Randomized clinical trial comparing removal followed by topical imiquimod versus removal followed by topical methylprednisolone in the treatment of keloids.
Ricciardi AS, Chedid MF, Thompson CE, Silva RKD, Azulay DR, Manela-Azulay M. Ricciardi AS, et al. Acta Cir Bras. 2025 Aug 25;40:e406225. doi: 10.1590/acb406225. eCollection 2025. Acta Cir Bras. 2025. PMID: 40862424 Free PMC article. Clinical Trial.
Four of the total eight keloids (50%) in the methylprednisolone group vs. 3/8 keloids (37.5%) in the imiquimod group recurred in the first post-treatment year (p 0.05). CONCLUSION: Surgical removal plus application of topical imiquimod was shown as safe, and its eff …
Four of the total eight keloids (50%) in the methylprednisolone group vs. 3/8 keloids (37.5%) in the imiquimod group recurred in the …
Randomized Phase II Trial of Imiquimod with or without 9-Valent HPV Vaccine versus Observation in Patients with High-grade Pre-neoplastic Cervical Lesions (NCT02864147).
Sheth SS, Oh JE, Bellone S, Siegel ER, Greenman M, Mutlu L, McNamara B, Pathy S, Clark M, Azodi M, Altwerger G, Andikyan V, Huang G, Ratner E, Kim DJ, Iwasaki A, Levi AW, Buza N, Hui P, Flaherty S, Schwartz PE, Santin AD. Sheth SS, et al. Clin Cancer Res. 2024 May 1;30(9):1768-1777. doi: 10.1158/1078-0432.CCR-23-3639. Clin Cancer Res. 2024. PMID: 38592381 Clinical Trial.
PURPOSE: We report the results of a randomized phase II trial of imiquimod, a topical immune-response modulator versus imiquimod plus a 9-valent human papillomavirus (HPV) vaccine (9vHPV) versus clinical surveillance in cervical intraepithelial neoplasia (CIN2/3) pa …
PURPOSE: We report the results of a randomized phase II trial of imiquimod, a topical immune-response modulator versus imiquimod …
A multicentre pragmatic randomized controlled trial comparing 50% salicylic acid, liquid nitrogen, 5% 5-fluorouracil cream, and 5% imiquimod cream in previously treated plantar warts. The VRAIE (VeRrues plAntaIres en villE) study.
Chanal J, Aubin F, Penso-Assathiany D, Buffière I, Makhlouf W, Perrière C, Bocquet H, Aubin A, Farcet Y, Ludmann C, Duboz A, Marco-Bonnet J, Maury C, Tremeau-Martinage C, Hubert-Asso AM, Coustou D, Heudes AM, Kemula M, Beylot-Barry M, Tétart F, Eche-Dejoie A, Duvochel AM, Baspeyras M, Amici JM, Toussaint H, Neculaita L, Mboup B, Pizzi N, Jouis V, Vacher Y, Prétet JL, Vicaut E, Chosidow O. Chanal J, et al. Ann Dermatol Venereol. 2025 Sep;152(3):103406. doi: 10.1016/j.annder.2025.103406. Epub 2025 Jul 30. Ann Dermatol Venereol. 2025. PMID: 40743833 Free article. Clinical Trial.
OBJECTIVES: To compare 4 second-line treatments - 50 % salicylic acid ointment (SA) under occlusion, liquid nitrogen, 5 % 5-fluorouracil (5-FU) cream under occlusion, and 5 % imiquimod cream - in terms of complete remission after 90 days. METHODS: A multicentre, pragmatic, …
OBJECTIVES: To compare 4 second-line treatments - 50 % salicylic acid ointment (SA) under occlusion, liquid nitrogen, 5 % 5-fluorouracil (5- …
Randomized clinical trial of imiquimod compared with fludroxycortide in the treatment of actinic cheilitis.
Fumagalli MJ, Cherubini K, Spanemberg JC, Salum FG. Fumagalli MJ, et al. Oral Surg Oral Med Oral Pathol Oral Radiol. 2025 Apr;139(4):423-429. doi: 10.1016/j.oooo.2024.12.002. Epub 2024 Dec 14. Oral Surg Oral Med Oral Pathol Oral Radiol. 2025. PMID: 39755449 Clinical Trial.
This study aimed to evaluate the topical effect of imiquimod 5% (IM) and fludroxycortide (FC) 0.125 mg/g creams in the treatment of AC. STUDY DESIGN: A randomized controlled trial was conducted. ...There was a significant difference between the groups in the clinical outco …
This study aimed to evaluate the topical effect of imiquimod 5% (IM) and fludroxycortide (FC) 0.125 mg/g creams in the treatment of A …
Randomised trial on treatment of vaginal high-grade squamous intraepithelial lesion: Self-administered vaginal imiquimod and laser vaporisation.
Kiviharju M, Riska A, Kalliala I, Jakobsson M, Heinonen A, Dillner J, Nieminen P, Aro K. Kiviharju M, et al. Int J Cancer. 2025 Oct 1;157(7):1458-1464. doi: 10.1002/ijc.35497. Epub 2025 Jun 2. Int J Cancer. 2025. PMID: 40454918 Free PMC article. Clinical Trial.
Genotype-specific post-treatment negativity for HPV occurred in 16.7% of the laser group and in 39.1% of the imiquimod group (p = 0.12). Imiquimod had short-term adverse effects, but 93% completed treatment as instructed. We conclude that vaginal imiquimod is …
Genotype-specific post-treatment negativity for HPV occurred in 16.7% of the laser group and in 39.1% of the imiquimod group (p = 0.1 …
Imiquimod Cream Preceded by Superficial Curettage vs Surgical Excision for Nodular Basal Cell Carcinoma: A Secondary Analysis of a Randomized Clinical Trial.
Verkouteren BJA, Nelemans PJ, Sinx KAE, Kelleners-Smeets NWJ, Winnepenninckx VJL, Arits AHMM, Mosterd K. Verkouteren BJA, et al. JAMA Dermatol. 2025 Mar 1;161(3):299-304. doi: 10.1001/jamadermatol.2024.5572. JAMA Dermatol. 2025. PMID: 39878970 Free PMC article. Clinical Trial.
For superficial BCC, it has been demonstrated that imiquimod cream, 5%, has high long-term efficacy, but for nodular BCC (nBCC), long-term evidence is sparse. ...CONCLUSIONS: This secondary analysis of a randomized clinical trial found that although it cannot be concluded …
For superficial BCC, it has been demonstrated that imiquimod cream, 5%, has high long-term efficacy, but for nodular BCC (nBCC), long …
327 results